AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainua) to treat adult ...

There is a lack of understanding among neurologists on how to balance the risks for and benefits of corticosteroids in ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty ...

Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

UK MHRA grants marketing authorisation to AstraZeneca’s eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Friday, October 18, 2024, ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...